Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?-Reference-Cited by-同舟云学术

Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?

Author:

Habibi Roojin¹^ORCID,Lexchin Joel²^ORCID,Mintzes Barbara³,Holbrook Anne⁴

Affiliation:

1. Faculty of Law; University of Ottawa; Ottawa Canada

2. School of Health Policy and Management; York University; Toronto Canada

3. Charles Perkins Centre and Faculty of Pharmacy; University of Sydney; Sydney Australia

4. Division of Clinical Pharmacology & Toxicology, Department of Medicine; McMaster University; Hamilton Canada

Funder

Michael Smith Foundation for Health Research

Institute of Health Services and Policy Research

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

Reference38 articles.

1. Office of Inspector General FDA's review process for new drug applications: a management review 2003

2. Health Products and Food Branch Access to therapeutic products: the regulatory process in Canada 2006

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献